Suzhou Pengxu Pharmatech Co., Ltd.

Crystal Pharmatech Co., Ltd.

Esteve Quimica S.a.

Crystal Pharmatech Inc.

Pixu Li

Peng Wang

Qiang Wei

Yanfeng Zhang

Minhua Chen

Xiaoyu Zhang

Chaohui Yang

Yuanhua Liu

Zhong Wang

Wen Cheng

Xiangyong Gu

Feng Gao

Jiaoyang Li

Fei Lu

Hao Wu

Qianghua Jiang

Heng Ge

Yadong Ge

Hailong Yang

Qiangqiang Du

Hui Xia

The present invention provides a scalable synthesis of enantiomerically pure brivaracetam, and related derivatives.

Processes to produce brivaracetam

The present application provides a upadacitinib salt compound and a preparation method therefor. The salt involved in the method in the present application has an easy preparation operation, a cheap raw material easy to get, and a good purification effect on upadacitinib, and is beneficial to industrial production.

Crystalline form of Di-p-toluoyl-L-tartrate of upadacitinib

The present disclosure relates to a JAK inhibitor upadacitinib intermediate and a preparation method therefor, and to a preparation method for a JAK inhibitor upadacitinib. The upadacitinib intermediate of the present application is as shown in Formula (II) or Formula (III),

Synthesis methods for upadacitinib and intermediate thereof

The present invention relates to a scalable process for the making of elagolix, its salts and the process of intermediate compounds.

Processes to produce elagolix

The present invention relates to a method for preparing the compound of formula IV, compound of formula XI, and acalabrutinib, a new generation of bruton tyrosine kinase (BTK) inhibitor. 

Processes to produce acalabrutinib

Novel crystalline forms of lesinurad and its sodium salt, processes for their preparation, pharmaceutical compositions comprising these new forms, and use of them for treating or delaying progression or onset of diseases or disorders related to activity of uric acid transporter 1 (URAT1) proteins are disclosed. These novel forms were characterized by X-ray powder diffraction, differential scanning calorimetry, and other techniques. They can be readily prepared and are suitable for preparation of solid dosage forms owing to their ease of handling and superior pharmacological properties.

Crystalline forms of lesinurad and its sodium salt

Novel salts and cocrystals of lesinurad, processes for their preparation, pharmaceutical compositions comprising these new salt forms and co-crystals, and use of them for treating or delaying progression or onset of diseases or disorders related to activity of uric acid transport 1 (URAT1) proteins are disclosed. These novel forms were characterized by X-ray powder diffraction, differential scanning calorimetry, and other techniques. They can be readily prepared and are suitable for preparation of solid dosage forms owing to their ease of handling and superior pharmacological properties.

Salts and co-crystals of lesinurad

Novel crystalline Forms of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butyl carbamoyl) propionate-(S)-3'-methyl-T-(pentanoyl{2&#x2033;-(tetrazol-5-ylate)biphenyl-4&#x2032;-ylmethyl}amino)butyrate] hydrate, methods for their preparation, pharmaceutical compositions comprising these new forms, and use of them for treating or delaying progression or onset of diseases or disorders related to activity of angiotensin receptor 1 (AT1) blockage and neprilysin (NEP) inhibition, such as heart failure, are disclosed.

Crystalline forms of trisodium supramolecular complex comprising valsartan and AHU-377 and methods thereof

Crystalline Form I of ibrutinib, processes for its preparation, pharmaceutical compositions comprising the new Form, and use of Form I of ibrutinib for treating or delaying diseases or disorders related to activity of Bruton's tyrosine kinase (BTK) proteins are disclosed. The novel Form was characterized by X-ray powder diffraction, differential scanning calorimetry, and other techniques. It can be readily prepared and is suitable for use in the preparation of solid dosage forms.

Growing community of inventors

Suzhou, China

Pixu Li